Potentially ground-breaking long acting injectable (LAI) HIV regimens received federal approval quite some time ago: for HIV treatment (January 2021) and HIV prevention (December 2021). Both offer the potential to simplify medication regimens and improve adherence.
The following resources, released in mid-2022, may help HIV care agencies and patients get their heads around the complexities and pick up the pace for consideration and implementation of LAI options.
- TAP-in: How EHE Jurisdictions Can Increase Uptake of Long Acting Injectables (LAIs) for HIV Treatment is an August 2022 HRSA webinar that reviews the science of LAIs for HIV treatment; patient and provider challenges and successes; a panel discussion; and implementation recommendations. An upcoming TAP-in toolkit will present ideas for implementation of LAIs.
HRSA will soon announce the award of Increasing Uptake of Long-Acting Injectable Antiretrovirals Among People with HIV, a new project to develop LAI technical tools for Ryan White HIV/AIDS Program agencies.
- The Long Acting Agent Resource Center, launched in August 2022, presents information for prescribers and patients, featuring prescribing guidelines, billing information, a forum for clinicians, and a map of current state coverage policies. The website is a product of the AAHIVM, the American Academy of HIV Medicine.
- Out of the gate a bit earlier, relatively speaking, is Long-Acting Injectable Antiretroviral Therapy: Coverage and Cost-Sharing Considerations for RWHAP Clients, a June 2022 HRSA-funded fact sheet on coverage and cost-sharing considerations for LAI ART.